Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.52 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106966 | 0.91 | EPHX2 (0.44) | EPHX2HMOX1CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL5155703 | 0.90 | EPHX2 (0.57) | EPHX2HMOX1CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL1740304 | 0.87 | EPHX2 (0.44) | EPHX2HMOX1CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL6123596 | 0.86 | EPHX2 (0.48) | EPHX2HMOX1CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL595897 | 0.84 | HMOX1 (0.52) | EPHX2HMOX1CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL595896 | 0.84 | HMOX1 (0.52) | EPHX2HMOX1CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL30729521 | 0.82 | KDM5A (0.58) | EPHX2HMOX1RIPK1RBP4KDM5A | |
| SCHEMBL23580500 | 0.80 | SPR (0.42) | HMOX1SPR | |
| SCHEMBL7900769 | 0.80 | PIK3CD (0.56) | — | |
| SCHEMBL23580503 | 0.80 | SPR (0.42) | HMOX1SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8618117-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2389382-B1 | Amino-heterocyclic compounds used as pde9 inhibitors | PFIZER (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PFIZER INC. | 2012-12-27 | — | — | US | disclosed |
| US-8278295-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2389382-A1 | Amino-heterocyclic compounds used as pde9 inhibitors | Pfizer Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8041687-B2 | Dynamic generation of XML Schema for backend driven data validation | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010084438-A1 | AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS | PFIZER INC. (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | EPHX2 1174/4885HMOX1 4235/4885CYP2C9 88/4885 |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | EPHX2 1174/4885HMOX1 4235/4885CYP2C9 88/4885 |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | EPHX2 1174/4885HMOX1 4235/4885CYP2C9 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.